MDCX Stock News & Catalysts

FEATURED

Medicus Pharma to Highlight Rationale for CD228V Co-Development and License Agreement

New

Capital efficiency strategy prioritizes CD228V development while seeking separate public listing for SkinJect® and partners to advance Teverelix® PHILADELPHIA, PA / ACCESS Newswire / November 9, 2026 / Medicus

Summary

Nov 9, 2026, 7:30 AM ·ACCESS Newswire

RECENT

Medicus Pharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Company Highlights CD228V as its Principal Development Priority, Proposed SPAC Business Combination at ~ $135 Million Valuation for SkinJect® and Teverelix® as a Partner-Ready Program PHILADELPHIA, PA / ACCESS

Nov 6, 2026, 4:30 PM ·ACCESS Newswire

Medicus Pharma to Present at BIO-Europe 2026

PHILADELPHIA, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided, biotech/life sciences company focused on advancing novel and

Nov 5, 2026, 7:30 AM ·Globe Newswire

Medicus Pharma to Host Third Quarter 2026 Financial Performance and Business Update Call on November 9, 2026

PHILADELPHIA, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided, biotech/life sciences company focused on advancing the clinical

Nov 4, 2026, 4:05 PM ·Globe Newswire

Medicus Pharma Announces Proposed SkinJect® Business Combination and Concurrent Financing

PHILADELPHIA, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided, biotech/life sciences company focused on advancing novel and

Nov 4, 2026, 8:30 AM ·Globe Newswire

Medicus Pharma to Present at BioFuture and Global Biotechnology Summit

PHILADELPHIA, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided, biotech/life sciences company focused on advancing novel and

Oct 27, 2026, 7:30 AM ·Globe Newswire

Medicus Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

PHILADELPHIA, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided, biotech/life sciences company focused on advancing novel and

Oct 26, 2026, 7:30 AM ·Globe Newswire

Medicus Pharma Highlights Three Years of Progress and Outlines Potential Path to Long Term Value

PHILADELPHIA, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided, biotech/life sciences company focused on advancing novel and

Oct 8, 2026, 8:00 AM ·Globe Newswire

Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer

PHILADELPHIA, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided, biotech/life sciences company focused on advancing novel and

Sep 29, 2026, 7:30 AM ·Globe Newswire

Medicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment

PHILADELPHIA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided, biotech/life sciences company focused on advancing novel and

Sep 21, 2026, 7:30 AM ·Globe Newswire

Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose

PHILADELPHIA, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided, biotech/life sciences company focused on advancing novel and

Sep 10, 2026, 7:30 AM ·Globe Newswire

Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company

PHILADELPHIA, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision-guided biotech/life sciences company focused on advancing the clinical

Sep 8, 2026, 7:30 AM ·Globe Newswire

Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Company Highlights Significant Regulatory, Clinical and Strategic Progress Across SkinJect® and Teverelix® Programs and a Strengthened Financial Position Supporting Continued Pipeline Execution and Expansion

Aug 12, 2026, 6:00 PM ·ACCESS Newswire

Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom

PHILADELPHIA, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of

Aug 3, 2026, 7:30 AM ·Globe Newswire

Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis

PHILADELPHIA, July 31, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of

Jul 31, 2026, 7:30 AM ·Globe Newswire

Medicus Pharma Ltd. Common Stock MDCX · News